article · PLoS ONE
INTRODUCTION: Lung cancer (LC) remains one of the most lethal malignancies worldwide. In Tunisia, LC population-level data is limited. This study aimed to estimate the incidence, mortality, trends burden and survival outcomes of LC over two decades in Monastir (Tunisia). METHODS: We conducted a retrospective population-based cohort including all LC patients diagnosed between 2002 and 2014 in the governorate of Monastir, with follow-up until 2022. Age-standardized incidence and mortality rates (ASIR and ASMR) were calculated and expressed per 100,000 Person-Years (PY). Trends were analyzed using Joinpoint regression to determine Annual Percent Change (APC). Disability-Adjusted Life Years (DALYs), Years of Life Lost (YLL), and Years Lived with Disability (YLD) were computed. Survival analysis was performed using Kaplan-Meier estimates, and multivariable Cox proportional hazards regression was used. RESULTS: LC ASIR per 100,000 PY was 18.37 (95% CI: 15.1-21.7), 33.63 (29.3-38.0) in males, and 4.50 (2.75-6.41) in females. ASMR per 100,000 PY was 12.33 (9.2-15.84), 24.84 (19.9-29.82) in males, and 2.0 (0.6-3.42) in females. Incidence showed a significant upward trend (APC 8.23%, 95% CI: 2.66-16.12), particularly in females (APC 17.99%, 95% CI: 9.86; 33.27). Projected ASIRs were 43.7 per 100,000 PY in 2025 (95% CI: 37.1-50.3) and 64.7 per 100,000 PY in 2030 (95% CI: 56.7-72.7). DALYs attributable to LC were 1,328 per 100,000 PY, comprising 1,198.8 YLLs and 129.2 YLDs. One-year and five-year survival rates were 43.2% (95% CI: 36.6-49.8) and 22.1% (95% CI: 17.4-26.8), respectively, with a median survival of 10 months (95% CI: 8.9-11.0). Survival was higher among females, younger patients (<65 years), and those diagnosed after 2009, with an improved median survival. CONCLUSION: LC incidence and mortality are rising, with low survival and a substantial burden of premature mortality, highlighting the urgent need for population-based prevention programs.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1371/journal.pone.0338140
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.